Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA) (COVID-19)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04322682
Recruitment Status : Recruiting
First Posted : March 26, 2020
Last Update Posted : August 3, 2020
Sponsor:
Collaborators:
National Heart, Lung, and Blood Institute (NHLBI)
Bill and Melinda Gates Foundation
The Government of Quebec
DACIMA Software
Information provided by (Responsible Party):
Montreal Heart Institute

Tracking Information
First Submitted Date  ICMJE March 23, 2020
First Posted Date  ICMJE March 26, 2020
Last Update Posted Date August 3, 2020
Actual Study Start Date  ICMJE March 23, 2020
Estimated Primary Completion Date September 2020   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: March 25, 2020)
Number of participants who die or require hospitalization due to COVID-19 infection [ Time Frame: 30 days post randomization ]
The primary endpoint will be the composite of death or the need for hospitalization due to COVID-19 infection in the first 30 days after randomization.
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: March 25, 2020)
  • Number of participants who die [ Time Frame: 30 days post randomization ]
    The secondary endpoint is the occurrence of death in the 30 days following randomization.
  • Number of participants requiring hospitalization due to COVID-19 infection [ Time Frame: 30 days post randomization ]
    The secondary endpoint is the need for hospitalization due to COVID-19 infection in the 30 days following randomization.
  • Number of participants requiring mechanical ventilation [ Time Frame: 30 days post randomization ]
    The secondary endpoint is the need for mechanical ventilation in the 30 days following randomization.
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA)
Official Title  ICMJE Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA)
Brief Summary This is a phase 3, multi-center, randomized, double-blind, placebo-controlled multicenter study to evaluate the efficacy and safety of colchicine in adult patients diagnosed with COVID-19 infection and have at least one high-risk criterion. Approximately 6000 subjects meeting all inclusion and no exclusion criteria will be randomized to receive either colchicine or placebo tablets for 30 days.
Detailed Description

The primary objective of this study is to determine whether short-term treatment with colchicine reduces the rate of death and lung complications related to COVID-19. The secondary objective is to determine the safety of treatment with colchicine in this patient population.

Approximately 6000 patients will be enrolled to receive either colchicine or placebo (1:1 allocation ratio) for 30 days. Follow-up assessments will occur at 15 and 30 days following randomization for evaluation of the occurrence of any trial endpoints or other adverse events.

Safety and efficacy will be based on data from randomized patients. An independent data and safety monitoring board (DSMB) will periodically review study results as well as the overall conduct of the study, and will make recommendations to the study Executive Steering Committee (ESC) to continue, stop or modify the study protocol.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:
This will be a randomized, double-blind, placebo-controlled, multi-center study. Following signature of the informed consent form, approximately 6000 subjects meeting all inclusion and no exclusion criteria will be randomized to receive either colchicine or placebo (1:1 allocation ratio) for 30 days. Follow-up phone or video assessments will occur at 15 and 30 days following randomization for evaluation of the occurrence of any trial endpoints or other adverse events.
Masking: Single (Participant)
Primary Purpose: Treatment
Condition  ICMJE Corona Virus Infection
Intervention  ICMJE
  • Drug: Colchicine
    Patients in this arm will receive study medication colchicine 0.5 mg per os (PO) twice daily for the first 3 days and then once daily for the last 27 days. If a dose is missed, it should not be replaced.
    Other Name: Immuno-modulatory
  • Drug: Placebo oral tablet
    Patients will receive the placebo 0.5 mg per os (PO) twice daily for the first 3 days and then once daily for the last 27 days. If a dose is missed, it should not be replaced.
Study Arms  ICMJE
  • Active Comparator: Colchicine 0.5 mg
    Patients will receive study medication colchicine 0.5 mg per os (PO) twice daily for the first 3 days and then once daily for the last 27 days. If a dose is missed, it should not be replaced.
    Intervention: Drug: Colchicine
  • Placebo Comparator: Placebo
    Patients will receive a placebo per os (PO) twice daily for the first 3 days and then once daily for the last 27 days. If a dose is missed, it should not be replaced.
    Intervention: Drug: Placebo oral tablet
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: March 25, 2020)
6000
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE September 2020
Estimated Primary Completion Date September 2020   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Males and females, at least 40 years of age, capable and willing to provide informed consent;
  2. Patient must have received a diagnosis of COVID-19 infection within the last 24 hours;
  3. Outpatient setting (not currently hospitalized or under immediate consideration for hospitalization);
  4. Patient must possess at least one of the following high-risk criteria: 70 years or more of age, obesity (BMI ≥ 30 kg/m2), diabetes mellitus, uncontrolled hypertension (systolic blood pressure ≥150 mm Hg), known respiratory disease (including asthma or chronic obstructive pulmonary disease), known heart failure, known coronary disease, fever of ≥38.4°C within the last 48 hours, dyspnea at the time of presentation, bicytopenia, pancytopenia, or the combination of high neutrophil count and low lymphocyte count;
  5. Female patient is either not of childbearing potential, defined as postmenopausal for at least 1 year or surgically sterile, or is of childbearing potential and practicing at least one method of contraception and preferably two complementary forms of contraception including a barrier method (e.g. male or female condoms, spermicides, sponges, foams, jellies, diaphragm, intrauterine device (IUD)) throughout the study and for 30 days after study completion;
  6. Patient must be able and willing to comply with the requirements of this study protocol.

Exclusion Criteria:

  1. Patient currently hospitalized or under immediate consideration for hospitalization;
  2. Patient currently in shock or with hemodynamic instability;
  3. Patient with inflammatory bowel disease (Crohn's disease or ulcerative colitis), chronic diarrhea or malabsorption;
  4. Patient with pre-existent progressive neuromuscular disease;
  5. Estimated Glomerular filtration rate (eGFR), using the MDRD equation for all subjects being considered for enrollment, with a cut-off of < 30 mL/m in/1.73m2;
  6. Patient with a history of cirrhosis, chronic active hepatitis or severe hepatic disease;
  7. Female patient who is pregnant, or breast-feeding or is considering becoming pregnant during the study or for 6 months after the last dose of study medication;
  8. Patient currently taking colchicine for other indications (mainly chronic indications represented by Familial Mediterranean Fever or gout);
  9. Patient with a history of an allergic reaction or significant sensitivity to colchicine;
  10. Patient undergoing chemotherapy for cancer;
  11. Patient is considered by the investigator, for any reason, to be an unsuitable candidate for the study.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 40 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Jean-Claude Tardif, MD 514-376-3330 ext 3612 jean-claude.tardif@icm-mhi.org
Contact: Zohar Bassevitch, B.SC. 514-461-1300 ext 2214 zohar.bassevitch@mhicc.org
Listed Location Countries  ICMJE Canada,   Spain,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT04322682
Other Study ID Numbers  ICMJE MHIPS-2020-001
3R01HL146206-02S1 ( U.S. NIH Grant/Contract )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Montreal Heart Institute
Study Sponsor  ICMJE Montreal Heart Institute
Collaborators  ICMJE
  • National Heart, Lung, and Blood Institute (NHLBI)
  • Bill and Melinda Gates Foundation
  • The Government of Quebec
  • DACIMA Software
Investigators  ICMJE
Principal Investigator: Jean-Claude Tardif, MD Montreal Heart Institute
Study Director: Zohar Bassevitch, B.SC. Montreal Health Innovations Coordinating Center
PRS Account Montreal Heart Institute
Verification Date July 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP